Positive ZEPHYR Trial Results Fail to Impress Investors as MapLight Stock Plunges

MapLight ZEPHYR trial: BID dose hits primary endpoint & cognitive goals, but QD misses; shares plunge over 60% on mixed schizophrenia data.